🆙#ESMO26 Presidential Symposium II: #LCSM

Hidehito HORINOUCHI· @HHorinouchi · X·2026-10-25 23:41· 17 小时前评分70

正文 · 原文

🆙#ESMO26 Presidential Symposium II: #LCSM
🔥Krascendo 1: Efficacy and Safety of Divarasib (Diva) vs Sotorasib (Soto) or Adagrasib (Ada) in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC
🎙️ @FSkoulidis
🔢LBA5
🎯Significantly Improved PFS (9.8 vs 5.7mo, HR 0.58; n=338) and OS (17.7 vs 12.0mo, HR 0.56, p=0.0005)
🎯ORR 58.4% vs 32.3%
🎯Discontinuation Due to TRAEs 4.8% vs 11.7%
☑️NCT06497556
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348
@OncoAlert @Larvol @myESMO @IASLC @KRASKickers

125 浏览 · 1 赞 · 1 转发 · 2 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

引用@

🆙#ESMO26 Presidential Symposium II: #LCSM 🔥Krascendo 1: Efficacy and Safety of Divarasib (Diva) vs Sotorasib (Soto) or Adagrasib (Ada) in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC 🎙️ @FSkoulidis 🔢LBA5 🎯Significantly Improved PFS (9.8 vs 5.7mo, HR 0.58; n=338) and OS (17.7 vs 12.0mo, HR 0.56, p=0.0005) 🎯ORR 58.4% vs 32.3% 🎯Discontinuation Due to TRAEs 4.8% vs 11.7% ☑️NCT06497556 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348 @OncoAlert @Larvol @myESMO @IASLC @KRASKickers

在 X 查看被引用的帖子

帖内回复

Hidehito HORINOUCHI@HHorinouchi
#ESMO26
Hidehito HORINOUCHI@HHorinouchi
#ESMO26

来源：Hidehito HORINOUCHI · x.com